PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.50%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
-488.33%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-14.77%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-14.77%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
-25.91%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
18928.57%
D&A growth above 10% signals heavy asset expansion. Seth Klarman would demand evidence of future payoff.
439.10%
EBITDA growth above 15% demonstrates exceptional operating performance. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
10.94%
Operating income growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
70.03%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-47.20%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
11.95%
Net income growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
11.92%
EPS growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
11.92%
Diluted EPS growth 8-12% reflects healthy expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.